Locally Advanced Triple-Negative Breast Carcinoma Clinical Trials

5 clinical trials for Locally Advanced Triple-Negative Breast Carcinoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer — RECRUITING · PHASE1
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Pembrolizumab and Cryoablation in People With Breast Cancer — RECRUITING · PHASE1
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer — RECRUITING · PHASE1
• Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer — WITHDRAWN · PHASE1

Refine this search